CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3/NF-κB/SDF-1α axis to enhance efficacy against pancreatic cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3/NF-κB/SDF-1α axis to enhance efficacy against pancreatic cancer

Published:2023-11 Issue:11 Volume:31 Page:3193-3209
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Sun Ruixin,Sun Yansha,Wu Chuanlong,Liu Yifan,Zhou Min,Dong Yiwei,Du Guoxiu,Luo Hong,Shi Bizhi,Jiang Hua,Li Zonghai

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference56 articles.

1. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia;Porter;Sci. Transl. Med.,2015

2. Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials.(2020);Shi;Clin. Cancer Res.,2020

3. CAR T-Cell Therapy in Large B-Cell Lymphoma;Neelapu;N. Engl. J. Med.,2018

4. Tumor microenvironment and cancer therapy resistance;Sun;Cancer Lett.,2016

5. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer;Kershaw;Clin. Cancer Res.,2006

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Suppressive immune microenvironment and CART therapy for glioblastoma: Future prospects and challenges;Cancer Letters;2024-09

2. Harnessing cytokines to optimize chimeric antigen receptor-T cell therapy for gastric cancer: Current advances and innovative strategies;Biomedicine & Pharmacotherapy;2024-09

3. Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: An updated review (from 2022 to 2024);Chinese Chemical Letters;2024-09

4. Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy;Molecular Cancer;2024-08-26

5. Dual targeting chimeric antigen receptor cells enhance antitumour activity by overcoming T cell exhaustion in pancreatic cancer;British Journal of Pharmacology;2024-08-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3